The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 10-1 in favor of approval for vorapaxar, Merck's novel thrombin receptor antagonist. The “roller coaster ride” cliché might have...
     |
FDA Advisory Panel Votes In Favor Of Approval For Merck’s Vorapaxar
The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 10-1 in favor of approval for vorapaxar, Merck's novel thrombin receptor antagonist. The “roller coaster ride” cliché might have...
